| Symbol | ACXP |
|---|---|
| Name | ACURX PHARMACEUTICALS, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 259 LIBERTY AVE, STATEN ISLAND, New York, 10305, United States |
| Telephone | +1 917 533-1469 |
| Fax | — |
| — | |
| Website | https://www.acurxpharma.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001736243 |
| Description | Acurx Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization, Centers for Disease Control and Prevention and Food and Drug Administration. Additional info from NASDAQ: |
New Form ARS - Acurx Pharmaceuticals, Inc. <b>Filed:</b> 2026-09-01 <b>AccNo:</b> 0001104659-26-104320 <b>Size:</b> 20 MB
Read moreNew Form DEFA14A - Acurx Pharmaceuticals, Inc. <b>Filed:</b> 2026-09-01 <b>AccNo:</b> 0001104659-26-104319 <b>Size:</b> 323 KB
Read moreNew Form DEF 14A - Acurx Pharmaceuticals, Inc. <b>Filed:</b> 2026-09-01 <b>AccNo:</b> 0001104659-26-104316 <b>Size:</b> 1 MB
Read moreAcurx Pharmaceuticals Receives FDA Conditional Acceptance and USPTO Trademark Allowance for the Companys Brand Name for Ibezapolstat
Read moreAcurx Pharmaceuticals, Inc. Reports Second Quarter 2026 results and provides business update
Read moreJapan and Mexico Patent Offices Both Grant Acurx Pharmaceuticals New Patents for DNA Polymerase IIIC Inhibitor Antibiotics
Read moreAcurx Announces Scientific Partnership with Leiden University Medical Center to Advance Development of Acurxs DNA Polymerase IIIC Inhibitor Antibiotics
Read moreFDA Provides Further Regulatory Guidance to Acurx Pharmaceuticals for the Ibezapolstat Clinical Development Program, Including the Potential for a Single-Phase 3-Trial Registration Plan and a Trial Design to Support Both Treatment and Reduction of Recurrence of C. difficile Infection
Read moreAcurx Pharmaceuticals Announces Presentation of Results from Leiden University Medical Center Public-Private Partnership for Its DNA pol IIIC Inhibitors at the Leiden Early Drug Discovery & Development (LED3) Scientific Conference
Read moreNew Form 424B3 - Acurx Pharmaceuticals, Inc. <b>Filed:</b> 2026-05-12 <b>AccNo:</b> 0001104659-26-059298 <b>Size:</b> 222 KB
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT07513285 | ACX-362E [Ibezapolstat] for Oral Treatment of Recurrent Clostridioides Difficil… | Phase2 | Clostridium Difficile Infection Recurrence | Recruiting | 2026-08-06 | 2027-11-24 | ClinicalTrials.gov |
| NCT04247542 | ACX-362E [Ibezapolstat] for Oral Treatment of Clostridioides Difficile Infection | Phase2 | Clostridium Difficile Infection | Completed | 2020-03-06 | 2023-11-15 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Ibezapolstat | Other | Phase PHASE2 | Clostridium Difficile Infection Recurrence | RECRUITING | NCT07513285 |
| Vancomycin | Other | Phase PHASE2 | Clostridium Difficile Infection | COMPLETED | NCT04247542 |
| Ibezapolstat | Other | Phase PHASE2 | Clostridium Difficile Infection | COMPLETED | NCT04247542 |
| Placebo | DRUG | Phase PHASE3 | Tardive Dyskinesia | COMPLETED | NCT02291861 |
| SD-809 | DRUG | Phase PHASE1 | TOURETTE SYNDROME | COMPLETED | NCT02674321 |
| Vancomycin | DRUG | Phase PHASE2 | Clostridium Difficile Infection | COMPLETED | NCT04247542 |
| Ibezapolstat | DRUG | Phase PHASE2 | Clostridium Difficile Infection Recurrence | NOT_YET_RECRUITING | NCT07513285 |